

**CAREFIRST - DC EXCHANGE 5T****Tazorac (HMF)**

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 888-836-0730. Please contact CVS/Caremark at 855-582-2022 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Tazorac (HMF).

**Patient Information**

Patient Name:	<input type="text"/>
Patient Phone:	<input type="text"/>
Patient ID:	<input type="text"/>
Patient Group:	<input type="text"/>
Patient DOB:	<input type="text"/>

**Physician Information**

Physician Name	<input type="text"/>
Physician Phone:	<input type="text"/>
Physician Fax:	<input type="text"/>
Physician Addr.:	<input type="text"/>
City, St, Zip:	<input type="text"/>

**Drug Name (select from list of drugs shown)**

Tazorac Cream 0.05% (tazarotene)    Tazarotene Gel 0.1%    Tazarotene Gel 0.05%    Tazarotene Cream 0.1%

Quantity:	_____	Frequency:	_____	Strength:	_____
Route of Administration:	_____	Expected Length of Therapy:	_____		
Diagnosis:	_____	ICD Code:	_____		
Comments:	_____				

**Please check the appropriate answer for each applicable question.**

- |    |  |   |                          |   |                          |
|----|--|---|--------------------------|---|--------------------------|
| 1. | Does the patient have a diagnosis of acne vulgaris?  | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 2. | Is the requested drug being prescribed for the treatment of plaque psoriasis?  | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 3. | Does the plaque psoriasis affect less than or equal to 20 percent of the patient's body surface area?  | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 4. | Is the request for continuation of therapy?  | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 5. | Has the patient experienced an inadequate treatment response to at least one topical corticosteroid? [Note: The patient may continue to use a corticosteroid product (e.g., clobetasol, fluocinonide, mometasone, triamcinolone, etc.).] | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 6. | Has the patient experienced an intolerance to at least one topical corticosteroid?   | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 7. | Does the patient have a contraindication that would prohibit a trial of topical corticosteroids?   | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 8. | Has the patient achieved or maintained a positive clinical response as evidenced by improvement (e.g., clear or almost clear outcome, patient satisfaction, etc.)?   | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

**Prescriber (Or Authorized) Signature and Date**

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to [www.caremark.com/epa](http://www.caremark.com/epa).